A distinct immunogenic region of glutamic acid decarboxylase 65 is naturally processed and presented by human islet cells to cytotoxic CD8 T cells

Clinical and Experimental Immunology

Volumn 179, Issue 1, 2015, Pages 100-107

  Knight, R R ^a   Dolton, G ^b   Kronenberg Versteeg, D ^a   Eichmann, M ^a   Zhao, M ^a   Huang, G C ^a   Beck, K ^b   Cole, D K ^b   Sewell, A K ^b   Skowera, A ^a,c   Peakman, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autoimmunity; CD8 T cell clones; GAD65; Peptide processing; Type 1 diabetes

Indexed keywords

EPITOPE; GLUTAMATE DECARBOXYLASE 65; HLA A ANTIGEN; TETRAMER; AUTOANTIGEN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; HLA A2 ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TARGET CELL; CELL LINE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PANCREAS ISLET;

ANTIGEN PRESENTATION; AUTOANTIGENS; CELL LINE; CLONE CELLS; EPITOPES, T-LYMPHOCYTE; GLUTAMATE DECARBOXYLASE; HLA-A2 ANTIGEN; HUMANS; ISLETS OF LANGERHANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84930398461     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12436     Document Type: Article

References (33)

1. von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 2013; 172:186-202.
2. Knight RR, Kronenberg D, Zhao M etal. Human beta-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 2013; 62:205-213.
3. Kronenberg D, Knight RR, Estorninho M etal. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 2012; 61:1752-1759.
4. Skowera A, Ellis RJ, Varela-Calvino R etal. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:3390-3402.
5. Velthuis JH, Unger WW, Abreu JR etal. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010; 59:1721-1730.
6. Fuchs YF, Adler K, Lindner A etal. IGRP and insulin vaccination induce CD8+ T cell-mediated autoimmune diabetes in the RIP-CD80GP mouse. Clin Exp Immunol 2014; 176:199-206.
7. Dolton G, Lissina A, Skowera A etal. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin Exp Immunol 2014; 177:47-63.
8. Coppieters KT, Dotta F, Amirian N etal. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51-60.
9. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155:173-181.
10. Nejentsev S, Howson JM, Walker NM etal., Wellcome Trust Case Control C. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007; 450:887-892.
11. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39:D913-919.
12. Nejentsev S, Howson JM, Walker NM etal. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007; 450:887-892.
13. Scotto M, Afonso G, Larger E etal. Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients. Diabetologia 2012; 55:2026-2031.
14. Li S, Li H, Chen B etal. Identification of novel HLA-A 0201-restricted cytotoxic T lymphocyte epitopes from Zinc Transporter 8. Vaccine 2013; 31:1610-1615.
15. Roep BO, Solvason N, Gottlieb PA etal. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes. Sci Transl Med 2013; 5:191ra82.
16. Vita R, Zarebski L, Greenbaum JA etal. The immune epitope database 2·0. Nucleic Acids Res 2010; 38:D854-862.
17. Boucherma R, Kridane-Miledi H, Bouziat R etal. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J Immunol 2013; 191:583-593.
18. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009; 126:147-164.
19. Roep BO, Peakman M. Diabetogenic T lymphocytes in human type 1 diabetes. Curr Opin Immunol 2011; 23:746-753.
20. Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148:1-16.
21. Panina-Bordignon P, Lang R, van Endert PM etal. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995; 181:1923-1927.
22. Monti P, Scirpoli M, Rigamonti A etal. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007; 179:5785-5792.
23. Monti P, Scirpoli M, Maffi P etal. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008; 118:1806-1814.
24. Mallone R, Scotto M, Janicki CN etal. T-Cell Workshop Committee IoDS. Immunology of diabetes society T-cell workshop: HLA class I tetramer-directed epitope validation initiative T-Cell Workshop Report-HLA Class I Tetramer Validation Initiative. Diabetes Metab Res Rev 2011; 27:720-726.
25. Giuliani L, Mele R, Di Giovine M etal. Detection of GAD65 autoreactive T-cells by HLA class I tetramers in type 1 diabetic patients. J Biomed Biotechnol 2009; 2009:576219.
26. Ekeruche-Makinde J, Miles JJ, van den Berg HA etal. Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood 2013; 121:1112-1123.
27. Thompson WS, Pekalski ML, Simons HZ etal. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol 2014; 177:571-585.
28. Huang GC, Zhao M, Jones P etal. The development of new density gradient media for purifying human islets and islet-quality assessments. Transplantation 2004; 77:143-145.
29. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995; 4:2411-2423.
30. Greenfield NJ. Analysis of circular dichroism data. Met Enzymol 2004; 383:282-317.
31. Venyaminov S, Baikalov IA, Shen ZM, Wu CS, Yang JT. Circular dichroic analysis of denatured proteins: inclusion of denatured proteins in the reference set. Anal Biochem 1993; 214:17-24.
32. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-219.
33. Erup Larsen M, Kloverpris H, Stryhn A etal. HLA restrictor-a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 2011; 63:43-55.